Quest Diagnostics (DGX)
(Delayed Data from NYSE)
$153.95 USD
-1.30 (-0.84%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $153.88 -0.07 (-0.05%) 7:58 PM ET
2-Buy of 5 2
B Value C Growth F Momentum B VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$153.95 USD
-1.30 (-0.84%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $153.88 -0.07 (-0.05%) 7:58 PM ET
2-Buy of 5 2
B Value C Growth F Momentum B VGM
Zacks News
AtriCure's Shares Likely to Benefit From New AtriClip Device Sales
by Zacks Equity Research
ATRC announces the treatment of the first patient using the AtriClip FLEX-Mini device.
Aveanna Stock Rallies 110% in 3 Months: Is It Still Worth Buying?
by Indrajit Bandyopadhyay
AVAH stock has the potential to continue its uptrend on the back of a better payer rate environment and its focus on high-paying customers.
Is HealthEquity Stock a Hold Now Amid Strong Top-Line Growth?
by Zacks Equity Research
HQY's sustained strength in HSAs raises optimism about the stock.
GE Healthcare to Unveil AI-Driven Cardiac Diagnostics at ESC 2024
by Zacks Equity Research
GEHC launches AI-enhanced ultrasound and ECG-less Cardiac CT technologies, offering rapid, accurate cardiac diagnostics at the point of care.
Quest Diagnostics Expands in North America With New Acquisition
by Zacks Equity Research
DGX acquires 100% of LifeLabs from OMERS, at approximately $1 billion. It will help LifeLabs to improve healthcare for Canadians.
MCK Stock's Uptrend Likely to Continue After Core Ventures Acquisition
by Zacks Equity Research
McKesson's agreement to acquire a controlling interest will likely bring advanced treatments and improved care experiences to patients.
Teleflex's (TFX) Titan SGS Stapler Showcases Positive Outcomes
by Zacks Equity Research
Teleflex (TFX) publishes an analysis of clinical data showcasing the Titan SGS Stapler's enhanced clinical outcomes and significant efficiency benefits.
Inari Medical (NARI) Issues Notice Post ClotTriever XL Recall
by Zacks Equity Research
Inari Medical (NARI) issues urgent updates to ClotTriever XL Catheter instructions following the FDA's recall after reports of serious injuries and deaths.
Ekso Bionics (EKSO) Addressable Market to Grow on CMS Update
by Zacks Equity Research
The CMS reimbursement is pivotal for Ekso Bionics (EKSO), as it opens up substantial opportunities in a market where cost has often been a barrier to access
Quest Diagnostics' (DGX) New Deal Aids Diagnostic Access in Ohio
by Zacks Equity Research
Quest Diagnostics (DGX) signs an agreement to acquire select assets of University Hospitals' outreach laboratory services business.
SI-BONE (SIBN) Receives FDA Nod for Its TNT Implant System
by Zacks Equity Research
SI-BONE (SIBN) receives FDA 510(k) clearance for its iFuse TORQ TNT implant system, followed by a Breakthrough Device Designation award by the FDA.
AtriCure's (ATRC) AtriClip Receives Expanded CE-Mark Indication
by Zacks Equity Research
AtriCure (ATRC) announces the receipt of an expanded CE-Mark indication for its AtriClip devices for reducing strokes in patients with Afib.
Microbot Medical (MBOT) Inks New Phase 2 Agreement for LIBERTY
by Zacks Equity Research
Microbot Medical (MBOT) signs a Phase 2 collaboration agreement with Corewell Health to advance remote telesurgery for endovascular procedures using LIBERTY.
INSPIRA (IINN) CART Gets FDA Listing, to Enhance Healthcare
by Zacks Equity Research
Inspira (IINN) announces FDA listing of its INSPIRA CART, designed for use with the ART100 system, enhancing healthcare delivery during cardiopulmonary bypass.
Henry Schein (HSIC) Hurt by Macroeconomic Woes, Cyber Attacks
by Zacks Equity Research
With sustained macroeconomic pressure, Henry Schein (HSIC) struggles to keep in check its cost of revenues and operating expenses.
Chemed (CHE) Up 5.7% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Chemed (CHE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Stryker's (SYK) Inks Deal to Aid Its Pain Management Portfolio
by Zacks Equity Research
Stryker (SYK) is set to acquire Vertos Medical to expand its interventional pain management portfolio.
Abbott (ABT) Gets FDA Approval for Aspirin-Free HeartMate 3 Regimen
by Zacks Equity Research
Abbott's (ABT) labeling update, exclusively for patients with a HeartMate 3 heart pump, secures the FDA's approval.
Cencora (COR) Gains 16.6% YTD: What's Driving the Stock?
by Zacks Equity Research
Cencora (COR) gaining traction from the robust U.S. Healthcare Solutions segment raises optimism about the stock.
PROCEPT BioRobotics' (PRCT) HYDROS System Gets FDA Clearance
by Zacks Equity Research
PROCEPT BioRobotics (PRCT) announces the FDA 510(k) clearance of its HYDROS Robotic System for providing better BPH treatment.
Quest Diagnostics (DGX) Up 6.3% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Quest Diagnostics (DGX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Cardinal Health (CAH) to Open New Distribution Center in Ohio
by Zacks Equity Research
Cardinal Health's (CAH) new center is set to integrate cutting-edge technology and automation, enhancing efficiency, storage capacity and quality of service.
Exact Sciences (EXAS) Rides on Cologuard Sales, New Launches
by Zacks Equity Research
Exact Sciences (EXAS) identifies more than 100 opportunities with payers and health systems to address the care gaps with Cologuard through screening programs.
Quest Diagnostics Incorporated (DGX) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Quest Diagnostics (DGX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
PROCEPT (PRCT) Grows in Urology With FDA Clearance for HYDROS
by Zacks Equity Research
PROCEPT's (PRCT) HYDROS Robotic System leverages AI-driven technology, specifically FirstAssist AI, to optimize treatment planning.